Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization

Overview

This study aims to evaluate the efficacy of the progestin-primed ovary stimulation (PPOS) protocol compared to the standard GnRH antagonist (GnRH\_ant) protocol across successive stages in a controlled ovarian stimulation (COS) and ICSI procedure.

Materials and Method This was an open-label, randomized controlled trial conducted at the Assisted Reproduction Center of Tam Anh General Hospital. The study aimed to estimate the efficacy of the intervention (PPOS protocol) compared to a control group receiving a gonadotropin-releasing hormone (GnRH) antagonist protocol. Sample size estimation The sample size estimation procedure is detailed in the study protocol. In brief, the investigators conducted a simulation that implied the method by Cundill and Alexander (2015) with parameters derived from the clinical profile of 804 patients who underwent ovarian stimulation by two protocols at Tam Anh Hospital from January to October 2022. The procedure aimed to optimize non-inferiority testing on the difference in the quantity of retrieved oocytes between two groups, estimated by a Negative Binomial distribution. The simulation result indicated that a total sample size of 200 patients (n=100 for each treatment arm) would be required to achieve a statistical power of 0.8. Recruitment of study participants Infertile patients come for examination at the Assisted Reproduction Center of Tam Anh General Hospital, Hanoi, and the Assisted Reproduction and Graft Technology Center of Hanoi Medical University. In the basic infertility examination process at the hospital, the clinicians will consider the patient's inclusive and exclusive criteria. The clinicians will contact a research team member if the inclusive criteria are met. A research team member or hospital physician will invite the patient to participate, advise on the study procedure and the benefits and risks of participating, and answer any patient questions. If the patients agree to participate, they will consent to participate in the trial. Each participant will be randomly assigned to the treatment group using the PPOS protocol or the control group using the GnRH-ant regimen. Treatment method Ovarian stimulation protocols Controlled ovarian hyperstimulation commenced on the second day of the menses utilizing recombinant follicle-stimulating hormone. In the gonadotropin-releasing hormone (GnRH) antagonist protocol group, pituitary suppression began on stimulation day six via daily 0.25 milligram GnRH antagonist administration (ganirelix or cetrorelix). In the progestin-primed ovarian stimulation (PPOS) group, 30mg/day of dydrogesterone was initiated on cycle day 2 through to trigger day. Laboratory protocol Oocyte-cumulus complexes were incubated for 2 hours in G-IVF medium (Vitrolife) using Origio benchtop incubators to complete nuclear maturation. After removing cumulus cells, denuded oocytes were evaluated under an inverted microscope to validate the achievement of metaphase II status, while degenerate, large, or severely dysmorphic oocytes were excluded. Intracytoplasmic sperm injection (ICSI) was executed 3-4 hours post-retrieval by experienced embryologists. Resultant zygotes were cultured in continuous single media (Fujifilm Irvine Scientific) within tri-gas incubators (37°C, 5% O2, 6% CO2) until day 3. Strict morphological criteria were enforced, only retaining normally fertilized two pronuclei zygotes while eliminating abnormal multinuclear embryos. Cleavage-stage quality was graded at 67-69 hours per Istanbul consensus based on cell number, fragmentation, multinucleation, and uniformity. On post-ICSI day 3, embryologists counseled patients on pursuing blastocyst culture versus cryopreservation. The morphology of the blastocysts was evaluated using the Gardner and Schoolcraft grading system, and embryos meeting the criteria of 3-6 AA/AB/BA blastocysts or 1-2 AA/AB embryos were classified as good quality.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts